Newport-based Xanodyne Pharmaceuticals Inc. has sold the global rights of women’s health product Lystedal to Ferring Pharmaceuticals, a privately owned specialty biopharmaceutical group headquartered in Switzerland. The sale is part of Xanodyne’s plan to tighten its focus on the pain management market, where it has a decade-long history with brands such as Darvocet and Roxicodone. The most recent addition to the company’s pain portfolio is Zipsor liquid-filled capsules, a non-steroidal anti-inflammatory drug that was approved by the FDA in June 2009. Financial details of the Xanodyne-Ferring transaction have not been disclosed.
-
Share This!
Newport
June 1, 2010
352 Views
You may also like
Popular Stories
Al Cross handicaps Kentucky’s political field
May 3, 2024
Kentucky falls to 41st in average teacher pay
May 3, 2024
The Lane Report
- Industry says Biden administration nursing home staffing levels mandate ‘impossible’ to meet
- $2M rare ‘unicorn’ bourbons raffle will benefit West End School
- Jeptha Creed Distillery Launches 6-Year Wheated Bourbon
- Al Cross handicaps Kentucky’s political field
- Kentucky falls to 41st in average teacher pay
- Markey’s Kolesar to lead national cancer research consortium
- U.S. adds 175,000 jobs; unemployment holds at 3.9%
- UofL Law Brandeis Medal will go to U.S. Supreme Court Justice Sotomayor
- Jennifer Moore creates Transy scholarship to empower future generations
- EKU occupational therapy program among nation’s best
Add Comment